US · Healthcare · Biotechnology
EPS came in at 15.72 against a street estimate of 1.46 — a beat of 976.7%.
Analysts rate Alnylam Pharmaceuticals Inc a buy (23 buy, 7 hold, 0 sell out of 30) with an average price target of $367.78.
MIXED Alnylam delivered strong TTR-led growth, but demand is below expectations, access risks cloud Q4, and Triton enrollment expansion underscores lower event-rate concerns. Q3 FY26 U.S. TTR revenue rose approximately 12% sequentially; international growth was led by Japan and Germany, partly offset by launch-price reductions. Analysts focused on Triton’s design and statistical power, commercial demand conversion, and potential 340B effects. Management defended the trial architecture while acknowledging access and execution risks. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 11.23% |
| Capital World Investors | 8.33% |
| BlackRock Inc | 8.15% |
| Capital Research Global Investors | 7.29% |
| Vanguard Portfolio Management, LLC | 4.89% |
| Vanguard Capital Management, LLC | 4.51% |
| T. Rowe Price Investment Management,Inc. | 4.22% |
| Amvescap Plc. | 2.81% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Alnylam’s Board authorized a program to repurchase up to $1.0 billion of common stock. • The company anticipates repurchasing app | 2026-11-05 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenue was $1,458,086, up from $1,249,026 in the third quarter of 2025. • Nine-month 2026 total revenu | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 global net product revenue was $1,292 million, up 52% from Q3 2025. • Total revenue was $1,458.086 million, up 17% year o | 2026-10-29 |
| Quarterly report · Q2 2026 ALNYLAM PHARMACEUTICALS, INC. – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net product revenues (Q2 2026): $1,172,109 tho | 2026-07-30 |
| Results announced · Q3 2026 ALNYLAM PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Global Net Product Revenues: $1,172 million (74% growth vs Q2 2025) • To | 2026-07-30 |
| Board / officer change · Q2 2026 ALNYLAM PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Board expanded from 10 to 11 directors effective June 1, 2026 • 133,427,910 shar | 2026-05-27 |
| Quarterly report · Q1 2026 ALNYLAM PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (Q1 2026): $1,167.2 million vs. $594.2 million (Q1 2025) — in | 2026-04-30 |
| Results announced · Q2 2026 ALNYLAM PHARMACEUTICALS Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 total net product revenues: $1,036 million (121% growth vs. Q1 2025) • Q | 2026-04-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorized up to $1 billion in common stock repurchases Alnylam announced that Tolga Tanguler, its Executive Vice President and Chief Commercialization Officer, will leave the company in December 2026. The company and Mr. Tanguler expect to sign | 2026-11-05 |
| 2025 preliminary results and 2026 combined net product revenue guidance provided Alnylam Pharmaceuticals announced strong 2025 preliminary revenues and unveiled a new five-year strategic plan called 'Alnylam 2030.' The company reported approximately $2.987 billion in ful | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alnylam Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.